Start here if you're new
what it is
Sensus sells low-dose radiation machines and software that help clinics treat skin cancer without surgery.
how it gets paid
Last year Sensus Healthcare made $27M in revenue.
why growth slowed
Revenue fell 34.3% last year. The 44.2% gross margin matters most because it says the machines are not the issue.
what just happened
The quarter looked loud on sales, with revenue at $23M, but the company still lost money.
At a glance
C++ balance sheet — some cracks in the foundation
20/100 earnings predictability — expect surprises
12.4x trailing p/e — the market's not buying it — or you found a deal
11.9% return on capital — nothing to write home about
$0.41 fy2024 eps est
xvary composite: 39/100 — weak
What they do
Sensus sells low-dose radiation machines and software that help clinics treat skin cancer without surgery.
This is hardware tied to workflow. Once your clinic buys one of Sensus's 3 SRT systems and trains staff, switching means new machines, new protocols, and reimbursement headaches. The company says its technology has treated hundreds of thousands of patients worldwide, which gives buyers real-world proof, not a lab demo.
How they make money
$27M
annual revenue · revenue declined -34.3% last year
total revenue
$27M
34.3%
The products that matter
radiotherapy device
SRT-100 Vision
core platform
It is the flagship system carrying a company that produced $27.5M in revenue last year and needs demand to recover fast.
turnaround driver
remote monitoring platform
Sensus Link
launched feb 2026
Launched in February 2026, it matters because SRTS needs something more repeatable than a business that just posted a 62% quarterly revenue drop.
recurring angle
customer financing
Financial Services
launched feb 2026
Also launched in February 2026, this unit is meant to remove upfront cost friction for clinics after a year that ended with a $7.7M net loss.
execution watch
Key numbers
37.5%
operating margin
Operating margin → profit after running the company → so what: Sensus lost 37.5 cents for every $1 of sales, so more revenue alone does not fix your problem.
12.4x
trailing p/e
P/E → stock price divided by earnings → so what: 12.4x looks cheap, but Yahoo Finance shows trailing EPS of -$0.24, so the earnings base is not clean.
$0M
long-term debt
Long-term debt → money owed over years → so what: no debt means Sensus is not sending scarce cash to lenders while it tries to stabilize sales.
11.9%
return on capital
Return on capital → profit from the money used in the business → so what: 11.9% is decent for a small device maker, but it clashes with the current loss profile.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 4 — safer than 20% of stocks
- price stability 5 / 100
- long-term debt $0M (0% of capital)
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for SRTS right now.
source: institutional data · return history unavailable
What just happened
missed estimates
The quarter looked loud on sales, with revenue at $23M, but the company still lost money.
Latest-quarter revenue rose 227% vs. prior year to $23M, while EPS was -$0.28. Gross margin was 44.2%, which says the product still has value, but the cost structure is the problem.
$23M
revenue
-$0.28
eps
44.2%
gross margin
the number that mattered
The 44.2% gross margin matters most because it says the machines are not the issue. The cost stack above gross profit is.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The #1 risk is clinic purchase delays inside a concentrated customer base.
high
customer concentration
Your top 10 customers accounted for 73% of revenue last year. In a $27.5M business, losing one meaningful account hurts fast.
high exposure to a small number of buyers
high
reimbursement thesis fails
The turnaround case depends on new CPT billing-code support translating into real clinic demand. If adoption stays slow, the hoped-for rebound to $31.7M revenue gets harder to justify.
pressures both sales recovery and credibility
med
new financing arm adds complexity
Financial Services launched in February 2026 to help clinics buy equipment. That may remove friction. It also asks a $64M company coming off a $7.7M loss to execute a second business model at the same time.
execution risk rises before results do
med
volatile trading can swamp fundamentals
Price stability is 5 / 100. Even if the business improves, the stock can still trade like a small-cap headline machine.
you may be right on the business and still hate the path
A company that lost $7.7M last year cannot afford many more quarters like a $4.9M revenue Q4, especially with 73% of sales tied to its top 10 customers.
source: institutional data · regulatory filings · risk analysis
Pay attention to
the number
revenue versus the $31.7M consensus
Analysts expect about 15% growth from last year's $27.5M. If management cannot even point toward that level, the rebound story slips again.
product
Sensus Link adoption
This launched in February 2026. You want proof it creates usage data, stickier customer relationships, or recurring revenue rather than just another slide in a deck.
calendar
first full quarter with the financing arm
Financial Services is new. The first few quarters should tell you whether it is helping clinics buy systems or just adding operational noise.
risk
customer concentration staying elevated
Top-10 customers were 73% of revenue last year. If that number does not come down, each large account keeps carrying outsized weight.
Analyst rankings
earnings predictability
20 / 100
This score is low because the business is small, order-driven, and volatile. In human-speak, analysts do not trust quarter-to-quarter consistency here.
street stance
5 firms
Coverage shows one sell, one hold, and three buy ratings, with published targets ranging from $6 to $8. That is optimism with caveats, not broad conviction.
source: institutional data
Institutional activity
institutional ownership data for SRTS is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$5
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive